4d Pharma Share Discussion Threads

[rjmahan] 14/2/2019 13:05

Only back to where we were last year.
Not much if this really works.

[someuwin] 04/2/2019 12:18

Jan 29, 2019 New York based Chardan Capital Markets issued a note on DDDD with target price of 400p.

[someuwin] 03/2/2019 21:15

...What are these pics? Stills from Breaking Bad? Nope. Just a glimpse of 4D's state of the art pharmaceutical grade facility. Capable of producing live biotherapeutics at both clinical and production scale...

End to end manufacturing capability

To meet our clinical development targets we have invested in a state-of-the-art, GMP-certified ~1,500 m² manufacturing facility. This gives us an end to end development capability, allowing us to scale our products from glassware in the lab to commercial-scale production. From 5L pilot-scale through to 3000L fermentation we optimise the development of our products in-house, without relying on external manufacturers.

Reproducible and consistent process

The ability to manufacture our products consistently and reproducibly defines our leading position in the microbiome space. Live biotherapeutics are complex products, with the potential to change between batches and over time if not properly controlled. This problem is multiplied exponentially if the product contains multiple organisms. Our single-strain approach allows us to retain exquisite control over the identity, purity, potency and stability of our products. Our in-house development and manufacturing team has more than 15 years’ experience in microbial fermentation.

[pugugly] 31/1/2019 16:11

someuwin - thanks -

[ch1ck] 31/1/2019 14:45

Interested I'm in

[someuwin] 31/1/2019 14:44

Remember:

Chairman, CEO, Chief Scientific Officer and NXD spent collectively £310,563 buying DDDD stock last month.

...They know what's going on.

[ch1ck] 31/1/2019 14:32

Stock is up 12%. Which is great.Something maybe brewing.It has a tendency to pop up on a bit of a run .I'll buy if the price cuts back

[someuwin] 31/1/2019 14:07

Will let you buy £3k online. but not £4k.

[someuwin] 30/1/2019 12:51

Yup - Pharma trial take a long time and a lot of money.

But 4D are at the forefront of the Pharmaceutical commercialisation of microbiome therapeutics (one of the hottest areas of new medical research). Which is why I am firmly of the belief that we will see some kind of corporate action soon.

Either an outright takeover or a major JV, partnership etc.

Amongst others, 4D are working with Merk & Co ($200bn valuation) on collaboration with their blockbuster drug Keytruda which has sales of $1.67 billion last year.

Their IP portfolio is worth many multiples of share price imo...

"One measure of success of our research is the development of our intellectual property estate and 4D continues to lead the field. We now have 355 granted patents across 46 patent families. As our teams uncover new bacteria that are therapeutically relevant, and unpick the mechanism of action or develop novel production techniques, the intellectual property estate will continue to grow in size and value."

[pugugly] 30/1/2019 12:11

L2 showing buy quote at 105.5 for 3,600 shares - A fair bit of activity at 114 & 113 buying from sellers on L2

Apart from the note you mention above - no news -

Can anyone interpret in simple rather than biological English - Implications? but a very very long time (I am guessing) to any cash generation.

[someuwin] 30/1/2019 11:54

No buy quote for just £2k.

[someuwin] 29/1/2019 07:08

RNS
RNS Number : 3214O
4d Pharma PLC
29 January 2019

4D pharma plc
(the "Company" or "4D")
Publication of data in connection with MRx0518

4D pharma announces publication of data highlighting immuno-stimulatory properties of MRx0518
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the publication of a paper outlining the mechanism and strong immuno-stimulatory effects of MRx0518.

The paper 'The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant' (Lauté-Caly et al) is published in the Nature Publishing Group journal Scientific Reports.

4D researchers demonstrated that MRx0518 stimulates both the innate and adaptive immune systems and identified the bacterial flagellin (a specific component of the MRx0518 bacterium) that interacts with the host TLR5 receptors as a mediator of this process. The TLR5 pathway is known to be associated with the body's response to cancer.

Dr Alex Stevenson, 4D's Chief Scientific Officer, commented: "This publication exemplifies our commitment to conducting leading microbiome research and further highlights the importance of a strain-level understanding of function and mechanism in selecting live biotherapeutic candidates for clinical development."

4D is conducting a number of clinical trials with MRx0518 across a range of settings in 2019. The first of which, a combination study with Keytruda® in collaboration with Merck & Co., Inc., Kenilworth, NJ., USA, and conducted at MD Anderson Cancer Centre, is open for recruitment.

Please find a copy of the paper here: www.nature.com/articles/s41598-018-36926-8

[someuwin] 08/1/2019 09:00

Two new NEDs having held senior positions at top Pharma cos..

Xencor (XNCR 2.2bn valuation) and Celgene (CELG 61bn valuation).

Something big is brewing here imo.

watch this space.

[someuwin] 08/1/2019 07:32

08 January 2019

4D pharma plc

(the "Company" or "4D")

Appointment of independent Non-Executive Directors

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the appointment of Ed Baracchini, PhD, and Professor Axel Glasmacher, MD, as independent Non-Executive Directors with immediate effect.

Ed Baracchini, PhD, was previously the Chief Business Officer at Xencor Inc. where he led strategic alliances and licensing. During his time at Xencor he negotiated license agreements with Novartis ($2.6B: immune-oncology bispecific antibodies), Novo Nordisk ($600M: drug discovery collaboration), Amgen ($500M: option and development agreement autoimmune disease antibody) among numerous others. Prior to that he served as SVP Business Development for Metabasis Therapeutics.

Professor Dr. med. Axel Glasmacher was until recently Senior Vice President and Head of the Global Clinical Research and Development Hematology-Oncology at Celgene, where he has worked in various roles for more than ten years. His work at Celgene led to the approvals of Revlimid®, Idhifa®, and Vidaza® (haematological cancers). He also worked on the PD-L1 inhibitor durvalumab. Prior to Celgene, Professor Glasmacher worked within the fields of hematology-oncology at the University Hospital in Bonn.

Duncan Peyton, 4D's Chief Executive Officer, commented: "We welcome Axel and Ed to our Board with great pleasure. Their collective experience will strengthen our commercial and therapeutic focus, as 4D accelerates development of its extensive pipeline in cancer and other immunological diseases."

[someuwin] 07/1/2019 09:25

Chairman, CEO, Chief Scientific Officer and NXD spent collectively £310,563 buying DDDD stock last month.

[someuwin] 07/1/2019 08:41

07 January 2019

4D pharma plc

(the "Company" or "4D")

Collaboration with MD Anderson Cancer Center

4D pharma and MD Anderson Cancer Center to Evaluate Live Biotherapeutics in Solid Tumours

4D pharma plc (AIM: DDDD) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings.

The alliance brings together MD Anderson's translational medicine and clinical research capabilities with 4D's expertise in the discovery and development of Live Biotherapeutics. The collaboration will initially assess 4D's lead oncology candidate, MRx0518, as a potential treatment for solid tumours.

The first clinical study, an open label Phase I study of MRx0518 in combination with Keytruda(R) and conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ., USA, has been initiated and is due to open shortly. The study will enrol up to 132 patients with metastatic cancer across multiple histologies (non-small cell lung cancer, renal cell carcinoma, bladder cancer and melanoma) who have failed prior anti-PD-1 therapy.

Subsequent studies are also being planned under the collaboration, including using MRx0518 in combination with stereotactic body radiotherapy (SBRT) for the treatment of pancreatic cancer.

Duncan Peyton, 4D's Chief Executive Officer, commented: "This alliance will provide a strong and long-term foundation for the development of 4D's Live Biotherapeutics in cancer."

He added, "The current study, which will be one of the first Live Biotherapeutic programmes to reach the clinic in the immuno-oncology space, represents an important step forward in the development of MRx0518 and 4D's broader oncology franchise. We look forward to continuing to work with our partners at MD Anderson to progress this study and help bring this therapy to patients."

Live biotherapeutics employ strains of gut bacteria that have been isolated from healthy human donors, and which are encapsulated, administered orally and delivered to the gut as a therapeutic. Each strain is selected for its functionality to perform a specific role in combatting a disease.

"MD Anderson is focused on providing the best possible care for cancer patients, including implementing the latest new treatment modalities," said Shubham Pant, MBBS, associate professor of Investigational Cancer Therapeutics at MD Anderson. "The gut microbiome has emerged as an important next-generation target in cancer therapy and we hope that live biotherapeutics will have the potential to make a significant difference for patients across a range of cancers."

[rjmahan] 23/12/2018 21:39

pyramid scheme.

[sparky333] 23/12/2018 09:52

Initiative Q is an attempt by ex-PayPal guys to create a new payment system instead of payment cards that were designed in the 1950s. The system uses its own currency, the Q, and to get people to start using the system once it's ready they are allocating Qs for free to people that sign up now (the amount drops as more people join - so better to join early). Signing up is free and they only ask for your name and an email address. There's nothing to lose but if this payment system becomes a world leading payment method your Qs can be worth a lot. If you missed getting bitcoin seven years ago, you wouldn't want to miss this.Here is my invite link: https://initiativeq.com/invite/ysfoTKwF2This link will stop working once I'm out of invites. Let me know after you registered, because I need to verify you on my end.

[pugugly] 20/12/2018 10:47

mustau - Agreed and market seems to have noted with selling pressure (all be it small) building again -
New target dwonside?

[mustau] 19/12/2018 08:49

With all these director buys can’t be much news on the horizon in the near term.

[fillipe] 13/12/2018 09:49

Well, that didn't make the ducks fly off the water.

f

[sparky333] 13/12/2018 08:48

Why would you sell when directors have just bought nearly 250,000 between themTraders baffle me